WVU Cancer Institute enrolls first patients in breast cancer vaccine trial
MORGANTOWN, W.Va. – The WVU Cancer Institute has enrolled two of the first three patients in a national clinical trial for a novel breast cancer vaccine.
The trial, sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, will examine the recommended biologic dose of a vaccine in combination with pembrolizumab, an immunotherapy drug that is used to fight certain cancers, in the treatment of patients with advanced triple-negative breast cancer.
“This vaccine works differently than traditional vaccines by helping to stimulate an immune response, which will enable the immunotherapy agent to uncloak and attack the cancer,” Sobha Kurian, M.D., WVU Medicine hematologist/oncologist and primary investigator of the study, said. “The immunotherapy by itself may not work against certain cancers because the cancer cells cloak themselves and often cannot be detected by the immune system, but this vaccine may help to overcome this problem.”
The WVU Cancer Institute joins 10 other cancer centers across the country in recruiting 29 patients for this study.
“The ability to participate in this study exemplifies the WVU Cancer Institute’s role as a leader in cancer research,” Dr. Kurian said. “The field of breast cancer research is constantly evolving, and we are honored to be at the forefront.”
Patients who receive the treatment will be closely monitored for up to 90 days to assess the efficacy of the drug and vaccine combination.
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.
To date, the Norma Mae Huggins Cancer Research Endowment Fund has raised about $5 million to support clinical research trials for cancer patients in West Virginia. But, to the patients and physicians impacted by those funds, their value is priceless. To learn more, click here.
Related News
-
WVU Medicine J.W. Ruby Memorial Hospital earns National Pancreas Foundation Center designation
WVU Medicine J.W. Ruby Memorial Hospital has been nationally recognized as an approved NPF Center by the National Pancreas Foundation. NPF Centers are awarded after a rigorous audit review to determine that an institution’s focus is on multidisciplinary treatment of pancreatitis, treating the “whole patient” with a focus on the best possible outcomes and an improved quality of life.
-
WVU Medicine Children’s offering telemedicine, in-person appointments in Parkersburg area
Specialists from WVU Medicine Children’s are now providing appointments for families in the Parkersburg area.
-
WVU Heart and Vascular Institute receives national recognition as Top Mitral Valve Repair Reference Center
The WVU Heart and Vascular Institute has received the prestigious Mitral Valve Repair Reference Center Award from the American Heart Association and the Mitral Foundation for demonstrating a consistent record of high volumes, superior clinical outcomes, and durability resulting from mitral valve repair. The national recognition by an expert panel of cardiologists and surgeons from across the United States places the WVU Heart and Vascular Institute as one of the top 10 heart programs for mitral valve surgery in the country.